{"id":5858,"date":"2024-03-22T11:35:26","date_gmt":"2024-03-22T11:35:26","guid":{"rendered":"https:\/\/aceoncology.org\/?post_type=ace_education&#038;p=5858"},"modified":"2024-06-12T20:45:05","modified_gmt":"2024-06-12T20:45:05","slug":"best-practice-exchange-in-clinical-case-scenarios-learning-from-experts-on-urothelial-cancer-session-1","status":"publish","type":"ace_education","link":"https:\/\/aceoncology.org\/zh-hans\/education\/best-practice-exchange-in-clinical-case-scenarios-learning-from-experts-on-urothelial-cancer-session-1\/","title":{"rendered":"Session 1: Reconsidering the optimization of first-line treatment strategies in locally advanced or metastatic urothelial cancer"},"content":{"rendered":"\n<p>The therapeutic landscape of unresectable locally advanced or metastatic (LA\/m) urothelial cancer (UC) has undergone a significant transformation in recent years with the addition of immune checkpoint inhibitors (ICIs) targeting PD-1\/PD-L1 and novel antibody-drug conjugates (ADCs) to the treatment armamentarium. In real-world practice, factors such as drug accessibility, clinical characteristics, adverse events, and patient preferences greatly influence treatment decisions across diverse geographical regions. Therefore, it is crucial to develop an optimal treatment strategy tailored to the individual needs of patients in the first-line (1L) setting. In this educational program on \u2018Best Practice Exchange in Clinical Case Scenarios\u2019, experts in the field will discuss the latest evidence supporting the use of these therapies in clinical practice, including patient selection criteria for platinum eligibility and ineligibility, optimal 1L treatment strategies and immunotherapy maintenance approaches, considerations for treatment sequencing, and management of treatment-related adverse events (TRAEs). An improved understanding of the role and application of individual 1L treatment strategies in routine patient care will facilitate optimal management for patients with urothelial cancer.<\/p>\n\n\n\n<div style=\"height:7px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p>This English program is available with subtitles in the following languages:<\/p>\n\n\n\n<div style=\"height:10px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<figure class=\"wp-block-image\"><img decoding=\"async\" src=\"https:\/\/aceoncology.org\/wp-content\/uploads\/2023\/05\/Screenshot-2023-05-10-144115.png\" alt=\"This image has an empty alt attribute; its file name is Screenshot-2023-05-10-144115.png\"\/><\/figure>\n","protected":false},"excerpt":{"rendered":"<p>The therapeutic landscape of unresectable locally advan [&hellip;]<\/p>\n","protected":false},"author":719,"featured_media":5856,"template":"","ace_education_category":[101,68],"ace_education_tag":[],"class_list":["post-5858","ace_education","type-ace_education","status-publish","has-post-thumbnail","hentry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v25.8 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Session 1: Reconsidering the optimization of first-line treatment strategies in locally advanced or metastatic urothelial cancer - ACE Oncology<\/title>\n<meta name=\"description\" content=\"Reconsidering the optimization of first-line treatment strategies in locally advanced or metastatic urothelial cancer\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/aceoncology.org\/zh-hans\/education\/best-practice-exchange-in-clinical-case-scenarios-learning-from-experts-on-urothelial-cancer-session-1\/\" \/>\n<meta property=\"og:locale\" content=\"zh_CN\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Session 1: Reconsidering the optimization of first-line treatment strategies in locally advanced or metastatic urothelial cancer - ACE Oncology\" \/>\n<meta property=\"og:description\" content=\"Reconsidering the optimization of first-line treatment strategies in locally advanced or metastatic urothelial cancer\" \/>\n<meta property=\"og:url\" content=\"https:\/\/aceoncology.org\/zh-hans\/education\/best-practice-exchange-in-clinical-case-scenarios-learning-from-experts-on-urothelial-cancer-session-1\/\" \/>\n<meta property=\"og:site_name\" content=\"ACE Oncology\" \/>\n<meta property=\"article:modified_time\" content=\"2024-06-12T20:45:05+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/aceoncology.org\/wp-content\/uploads\/2024\/03\/Best-Practice-Exchange-edu-600x400-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"600\" \/>\n\t<meta property=\"og:image:height\" content=\"400\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@ace_oncology\" \/>\n<meta name=\"twitter:label1\" content=\"\u9884\u8ba1\u9605\u8bfb\u65f6\u95f4\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 \u5206\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/aceoncology.org\/zh-hans\/education\/best-practice-exchange-in-clinical-case-scenarios-learning-from-experts-on-urothelial-cancer-session-1\/\",\"url\":\"https:\/\/aceoncology.org\/zh-hans\/education\/best-practice-exchange-in-clinical-case-scenarios-learning-from-experts-on-urothelial-cancer-session-1\/\",\"name\":\"Session 1: Reconsidering the optimization of first-line treatment strategies in locally advanced or metastatic urothelial cancer - ACE Oncology\",\"isPartOf\":{\"@id\":\"https:\/\/aceoncology.org\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/aceoncology.org\/zh-hans\/education\/best-practice-exchange-in-clinical-case-scenarios-learning-from-experts-on-urothelial-cancer-session-1\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/aceoncology.org\/zh-hans\/education\/best-practice-exchange-in-clinical-case-scenarios-learning-from-experts-on-urothelial-cancer-session-1\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/aceoncology.org\/wp-content\/uploads\/2024\/03\/Best-Practice-Exchange-edu-600x400-1.jpg\",\"datePublished\":\"2024-03-22T11:35:26+00:00\",\"dateModified\":\"2024-06-12T20:45:05+00:00\",\"description\":\"Reconsidering the optimization of first-line treatment strategies in locally advanced or metastatic urothelial cancer\",\"breadcrumb\":{\"@id\":\"https:\/\/aceoncology.org\/zh-hans\/education\/best-practice-exchange-in-clinical-case-scenarios-learning-from-experts-on-urothelial-cancer-session-1\/#breadcrumb\"},\"inLanguage\":\"zh-Hans\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/aceoncology.org\/zh-hans\/education\/best-practice-exchange-in-clinical-case-scenarios-learning-from-experts-on-urothelial-cancer-session-1\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"zh-Hans\",\"@id\":\"https:\/\/aceoncology.org\/zh-hans\/education\/best-practice-exchange-in-clinical-case-scenarios-learning-from-experts-on-urothelial-cancer-session-1\/#primaryimage\",\"url\":\"https:\/\/aceoncology.org\/wp-content\/uploads\/2024\/03\/Best-Practice-Exchange-edu-600x400-1.jpg\",\"contentUrl\":\"https:\/\/aceoncology.org\/wp-content\/uploads\/2024\/03\/Best-Practice-Exchange-edu-600x400-1.jpg\",\"width\":600,\"height\":400},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/aceoncology.org\/zh-hans\/education\/best-practice-exchange-in-clinical-case-scenarios-learning-from-experts-on-urothelial-cancer-session-1\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"ACE Oncology\",\"item\":\"https:\/\/aceoncology.org\/zh-hans\/chinese-home\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"\u5728\u7ebf\u6559\u80b2\",\"item\":\"https:\/\/aceoncology.org\/zh-hans\/education\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Session 1: Reconsidering the optimization of first-line treatment strategies in locally advanced or metastatic urothelial cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/aceoncology.org\/#website\",\"url\":\"https:\/\/aceoncology.org\/\",\"name\":\"ACE Oncology\",\"description\":\"ACE Oncology is a global independent medical education resource that provides evidence-based, high-quality educational solutions for clinicians that treat patients with cancer.\",\"publisher\":{\"@id\":\"https:\/\/aceoncology.org\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/aceoncology.org\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"zh-Hans\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/aceoncology.org\/#organization\",\"name\":\"ACE Oncology\",\"url\":\"https:\/\/aceoncology.org\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"zh-Hans\",\"@id\":\"https:\/\/aceoncology.org\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/aceoncology.org\/wp-content\/uploads\/2021\/05\/Logo.png\",\"contentUrl\":\"https:\/\/aceoncology.org\/wp-content\/uploads\/2021\/05\/Logo.png\",\"width\":156,\"height\":83,\"caption\":\"ACE Oncology\"},\"image\":{\"@id\":\"https:\/\/aceoncology.org\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/x.com\/ace_oncology\",\"https:\/\/www.linkedin.com\/company\/aceoncology\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Session 1: Reconsidering the optimization of first-line treatment strategies in locally advanced or metastatic urothelial cancer - ACE Oncology","description":"Reconsidering the optimization of first-line treatment strategies in locally advanced or metastatic urothelial cancer","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/aceoncology.org\/zh-hans\/education\/best-practice-exchange-in-clinical-case-scenarios-learning-from-experts-on-urothelial-cancer-session-1\/","og_locale":"zh_CN","og_type":"article","og_title":"Session 1: Reconsidering the optimization of first-line treatment strategies in locally advanced or metastatic urothelial cancer - ACE Oncology","og_description":"Reconsidering the optimization of first-line treatment strategies in locally advanced or metastatic urothelial cancer","og_url":"https:\/\/aceoncology.org\/zh-hans\/education\/best-practice-exchange-in-clinical-case-scenarios-learning-from-experts-on-urothelial-cancer-session-1\/","og_site_name":"ACE Oncology","article_modified_time":"2024-06-12T20:45:05+00:00","og_image":[{"width":600,"height":400,"url":"https:\/\/aceoncology.org\/wp-content\/uploads\/2024\/03\/Best-Practice-Exchange-edu-600x400-1.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_site":"@ace_oncology","twitter_misc":{"\u9884\u8ba1\u9605\u8bfb\u65f6\u95f4":"1 \u5206"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/aceoncology.org\/zh-hans\/education\/best-practice-exchange-in-clinical-case-scenarios-learning-from-experts-on-urothelial-cancer-session-1\/","url":"https:\/\/aceoncology.org\/zh-hans\/education\/best-practice-exchange-in-clinical-case-scenarios-learning-from-experts-on-urothelial-cancer-session-1\/","name":"Session 1: Reconsidering the optimization of first-line treatment strategies in locally advanced or metastatic urothelial cancer - ACE Oncology","isPartOf":{"@id":"https:\/\/aceoncology.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/aceoncology.org\/zh-hans\/education\/best-practice-exchange-in-clinical-case-scenarios-learning-from-experts-on-urothelial-cancer-session-1\/#primaryimage"},"image":{"@id":"https:\/\/aceoncology.org\/zh-hans\/education\/best-practice-exchange-in-clinical-case-scenarios-learning-from-experts-on-urothelial-cancer-session-1\/#primaryimage"},"thumbnailUrl":"https:\/\/aceoncology.org\/wp-content\/uploads\/2024\/03\/Best-Practice-Exchange-edu-600x400-1.jpg","datePublished":"2024-03-22T11:35:26+00:00","dateModified":"2024-06-12T20:45:05+00:00","description":"Reconsidering the optimization of first-line treatment strategies in locally advanced or metastatic urothelial cancer","breadcrumb":{"@id":"https:\/\/aceoncology.org\/zh-hans\/education\/best-practice-exchange-in-clinical-case-scenarios-learning-from-experts-on-urothelial-cancer-session-1\/#breadcrumb"},"inLanguage":"zh-Hans","potentialAction":[{"@type":"ReadAction","target":["https:\/\/aceoncology.org\/zh-hans\/education\/best-practice-exchange-in-clinical-case-scenarios-learning-from-experts-on-urothelial-cancer-session-1\/"]}]},{"@type":"ImageObject","inLanguage":"zh-Hans","@id":"https:\/\/aceoncology.org\/zh-hans\/education\/best-practice-exchange-in-clinical-case-scenarios-learning-from-experts-on-urothelial-cancer-session-1\/#primaryimage","url":"https:\/\/aceoncology.org\/wp-content\/uploads\/2024\/03\/Best-Practice-Exchange-edu-600x400-1.jpg","contentUrl":"https:\/\/aceoncology.org\/wp-content\/uploads\/2024\/03\/Best-Practice-Exchange-edu-600x400-1.jpg","width":600,"height":400},{"@type":"BreadcrumbList","@id":"https:\/\/aceoncology.org\/zh-hans\/education\/best-practice-exchange-in-clinical-case-scenarios-learning-from-experts-on-urothelial-cancer-session-1\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"ACE Oncology","item":"https:\/\/aceoncology.org\/zh-hans\/chinese-home\/"},{"@type":"ListItem","position":2,"name":"\u5728\u7ebf\u6559\u80b2","item":"https:\/\/aceoncology.org\/zh-hans\/education\/"},{"@type":"ListItem","position":3,"name":"Session 1: Reconsidering the optimization of first-line treatment strategies in locally advanced or metastatic urothelial cancer"}]},{"@type":"WebSite","@id":"https:\/\/aceoncology.org\/#website","url":"https:\/\/aceoncology.org\/","name":"ACE Oncology","description":"ACE Oncology is a global independent medical education resource that provides evidence-based, high-quality educational solutions for clinicians that treat patients with cancer.","publisher":{"@id":"https:\/\/aceoncology.org\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/aceoncology.org\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"zh-Hans"},{"@type":"Organization","@id":"https:\/\/aceoncology.org\/#organization","name":"ACE Oncology","url":"https:\/\/aceoncology.org\/","logo":{"@type":"ImageObject","inLanguage":"zh-Hans","@id":"https:\/\/aceoncology.org\/#\/schema\/logo\/image\/","url":"https:\/\/aceoncology.org\/wp-content\/uploads\/2021\/05\/Logo.png","contentUrl":"https:\/\/aceoncology.org\/wp-content\/uploads\/2021\/05\/Logo.png","width":156,"height":83,"caption":"ACE Oncology"},"image":{"@id":"https:\/\/aceoncology.org\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/ace_oncology","https:\/\/www.linkedin.com\/company\/aceoncology"]}]}},"_links":{"self":[{"href":"https:\/\/aceoncology.org\/zh-hans\/wp-json\/wp\/v2\/ace_education\/5858","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/aceoncology.org\/zh-hans\/wp-json\/wp\/v2\/ace_education"}],"about":[{"href":"https:\/\/aceoncology.org\/zh-hans\/wp-json\/wp\/v2\/types\/ace_education"}],"author":[{"embeddable":true,"href":"https:\/\/aceoncology.org\/zh-hans\/wp-json\/wp\/v2\/users\/719"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/aceoncology.org\/zh-hans\/wp-json\/wp\/v2\/media\/5856"}],"wp:attachment":[{"href":"https:\/\/aceoncology.org\/zh-hans\/wp-json\/wp\/v2\/media?parent=5858"}],"wp:term":[{"taxonomy":"ace_education_category","embeddable":true,"href":"https:\/\/aceoncology.org\/zh-hans\/wp-json\/wp\/v2\/ace_education_category?post=5858"},{"taxonomy":"ace_education_tag","embeddable":true,"href":"https:\/\/aceoncology.org\/zh-hans\/wp-json\/wp\/v2\/ace_education_tag?post=5858"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}